Phase II trial of N-methylformamide in advanced renal cancer

J. S. Abrams, N. Tait, H. Silva, M. Eisenberger, D. A. Van Echo, I. N. Olver, J. Aisner

Research output: Contribution to journalArticlepeer-review

Abstract

N-methylformamide (NMF) (800-1,000 mg/m2 i.v. day 1) was given to 14 patients with measurable, advanced renal cell carcinoma in this Phase II trial. Treatment was repeated every 28 days. Significant toxicities included drug-induced hepatitis along with moderate nausea and vomiting. No objective responses were seen although several patients had stable disease with treatment for prolonged periods. NMF is not an active agent in renal cell cancer when administered by this schedule.

Original languageEnglish (US)
Pages (from-to)41-42
Number of pages2
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume12
Issue number1
DOIs
StatePublished - Jan 1 1989
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II trial of N-methylformamide in advanced renal cancer'. Together they form a unique fingerprint.

Cite this